We provide you with 20 years of free, institutional-grade data for ITCI stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ITCI. Explore the full financial landscape of ITCI stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Halstead Michael | Sale | -10,475 | $131.19 | $1,374,215 | 2025-03-10 |
| Halstead Michael | Derivatives Exercise | 20,478 | 2025-03-10 | ||
| Mates Sharon | Sale | -29,977 | $131.19 | $3,932,683 | 2025-03-10 |
| Mates Sharon | Derivatives Exercise | 61,278 | 2025-03-10 | ||
| Neumann Mark | Sale | -8,688 | $131.19 | $1,139,779 | 2025-03-10 |
| Neumann Mark | Derivatives Exercise | 20,478 | 2025-03-10 | ||
| Durgam Suresh K. | Sale | -8,688 | $131.19 | $1,139,779 | 2025-03-10 |
| Durgam Suresh K. | Derivatives Exercise | 20,478 | 2025-03-10 | ||
| Neumann Mark | Sale | -3,709 | $128.2 | $475,494 | 2025-03-04 |
| Neumann Mark | Derivatives Exercise | 8,742 | 2025-03-04 | ||
| Halstead Michael | Sale | -6,261 | $128.2 | $802,660 | 2025-03-04 |
| Halstead Michael | Derivatives Exercise | 12,239 | 2025-03-04 | ||
| Mates Sharon | Sale | -16,978 | $128.2 | $2,176,580 | 2025-03-04 |
| Mates Sharon | Derivatives Exercise | 34,969 | 2025-03-04 | ||
| Durgam Suresh K. | Sale | -3,709 | $128.2 | $475,494 | 2025-03-04 |
| Durgam Suresh K. | Derivatives Exercise | 8,742 | 2025-03-04 | ||
| MARCUS JOEL S | Derivatives Exercise | 7,009 | 2025-02-26 | ||
| Neumann Mark | Sale | -4,729 | $127 | $600,583 | 2025-02-04 |
| Neumann Mark | Grant, award...etc | 11,017 | 2025-02-04 | ||
| Durgam Suresh K. | Sale | -4,730 | $127 | $600,710 | 2025-02-04 |
| Durgam Suresh K. | Grant, award...etc | 11,017 | 2025-02-04 | ||
| Halstead Michael | Sale | -5,691 | $127 | $722,757 | 2025-02-04 |
| Halstead Michael | Grant, award...etc | 11,017 | 2025-02-04 | ||
| Mates Sharon | Sale | -15,233 | $127 | $1,934,591 | 2025-02-04 |
| Mates Sharon | Grant, award...etc | 30,847 | 2025-02-04 | ||
| RIGGS RORY B | Grant, award...etc | 215 | $83.52 | 2025-01-03 | |
| Mates Sharon | Sale | -102,697 | $85.62 | $8,793,143 | 2024-12-06 |
| Mates Sharon | Derivatives Exercise | 102,697 | 2024-12-06 | ||
| Halstead Michael | Sale | -41,583 | $88.72 | $3,689,244 | 2024-11-14 |
| Halstead Michael | Derivatives Exercise | 41,583 | 2024-11-14 | ||
| RIGGS RORY B | Derivatives Exercise | 14,189 | 2024-10-15 | ||
| RIGGS RORY B | Grant, award...etc | 246 | $73.17 | 2024-10-02 | |
| Mates Sharon | Sale | -70,000 | $72.44 | $5,070,996 | 2024-08-30 |
| Mates Sharon | Derivatives Exercise | 70,000 | 2024-08-30 | ||
| Mates Sharon | Sale | -95,925 | $74.59 | $7,155,324 | 2024-08-28 |
| Mates Sharon | Derivatives Exercise | 95,925 | 2024-08-28 | ||
| Mates Sharon | Sale | -121,073 | $75.4 | $9,129,219 | 2024-08-23 |
| Mates Sharon | Derivatives Exercise | 121,073 | 2024-08-23 | ||
| Neumann Mark | Sale | -18,714 | $75.08 | $1,405,047 | 2024-08-20 |
| Neumann Mark | Derivatives Exercise | 18,714 | 2024-08-20 | ||
| VAN NOSTRAND ROBERT L | Grant, award...etc | 83 | $68.49 | 2024-07-02 | |
| RIGGS RORY B | Grant, award...etc | 262 | $68.49 | 2024-07-02 | |
| MARCUS JOEL S | Derivatives Exercise | 1,567 | 2024-06-25 | ||
| VAN NOSTRAND ROBERT L | Derivatives Exercise | 1,567 | 2024-06-25 | ||
| RIGGS RORY B | Sale | -4,462 | $75.57 | $337,193 | 2024-06-25 |
| RIGGS RORY B | Derivatives Exercise | 21,567 | 2024-06-25 | ||
| Salas Eduardo Rene | Derivatives Exercise | 1,567 | 2024-06-25 | ||
| VAN NOSTRAND ROBERT L | Sale | -20,000 | $75.71 | $1,514,200 | 2024-06-21 |
| VAN NOSTRAND ROBERT L | Derivatives Exercise | 20,000 | 2024-06-21 | ||
| Mates Sharon | Derivatives Exercise | 20,020 | 2024-04-25 | ||
| RIGGS RORY B | Grant, award...etc | 260 | $69.2 | 2024-04-02 | |
| VAN NOSTRAND ROBERT L | Grant, award...etc | 79 | $69.2 | 2024-04-02 | |
| RIGGS RORY B | Derivatives Exercise | 20,000 | 2024-03-22 | ||
| Durgam Suresh K. | Derivatives Exercise | 7,345 | 2024-03-11 | ||
| Durgam Suresh K. | Sale | -10,162 | $66.34 | $674,147 | 2024-03-11 |
| Mates Sharon | Derivatives Exercise | 20,565 | 2024-03-11 | ||
| Mates Sharon | Sale | -61,277 | $66.38 | $4,067,567 | 2024-03-11 |
| Hineline Lawrence J. | Derivatives Exercise | 10,121 | 2024-03-11 | ||
| Hineline Lawrence J. | Sale | -23,253 | $66.26 | $1,540,744 | 2024-03-11 |
| Neumann Mark | Derivatives Exercise | 7,345 | 2024-03-11 | ||
| Neumann Mark | Sale | -20,477 | $66.37 | $1,359,058 | 2024-03-11 |
| Halstead Michael | Derivatives Exercise | 7,345 | 2024-03-11 | ||
| Halstead Michael | Sale | -20,477 | $66.14 | $1,354,349 | 2024-03-11 |
| Neumann Mark | Derivatives Exercise | 13,132 | 2024-03-08 | ||
| Mates Sharon | Derivatives Exercise | 40,712 | 2024-03-08 | ||
| Halstead Michael | Derivatives Exercise | 13,132 | 2024-03-08 | ||
| Durgam Suresh K. | Derivatives Exercise | 13,132 | 2024-03-08 | ||
| Hineline Lawrence J. | Derivatives Exercise | 13,132 | 2024-03-08 | ||
| VAN NOSTRAND ROBERT L | Sale | -20,000 | $72.71 | $1,454,200 | 2024-02-28 |
| VAN NOSTRAND ROBERT L | Derivatives Exercise | 20,000 | 2024-02-28 | ||
| Neumann Mark | Sale | -7,907 | $68.03 | $537,913 | 2024-02-27 |
| Neumann Mark | Derivatives Exercise | 7,907 | 2024-02-27 | ||
| MARCUS JOEL S | Sale | -26,328 | $67.83 | $1,785,828 | 2024-02-27 |
| MARCUS JOEL S | Derivatives Exercise | 36,757 | 2024-02-27 | ||
| Hineline Lawrence J. | Sale | -13,337 | $68.33 | $911,317 | 2024-02-27 |
| Hineline Lawrence J. | Derivatives Exercise | 13,337 | 2024-02-27 | ||
| Durgam Suresh K. | Sale | -4,112 | $69.38 | $285,291 | 2024-02-27 |
| Durgam Suresh K. | Derivatives Exercise | 7,907 | 2024-02-27 | ||
| Mates Sharon | Sale | -22,590 | $68.39 | $1,544,930 | 2024-02-27 |
| Mates Sharon | Derivatives Exercise | 22,590 | 2024-02-27 | ||
| Halstead Michael | Sale | -7,907 | $68.54 | $541,946 | 2024-02-27 |
| Halstead Michael | Derivatives Exercise | 7,907 | 2024-02-27 | ||
| Halstead Michael | Sale | -11,860 | $66.37 | $787,148 | 2024-02-05 |
| Halstead Michael | Grant, award...etc | 11,860 | 2024-02-05 | ||
| Mates Sharon | Sale | -33,885 | $66.7 | $2,260,130 | 2024-02-05 |
| Mates Sharon | Grant, award...etc | 33,885 | 2024-02-05 | ||
| Neumann Mark | Sale | -11,860 | $66.67 | $790,706 | 2024-02-05 |
| Neumann Mark | Grant, award...etc | 11,860 | 2024-02-05 | ||
| Hineline Lawrence J. | Sale | -11,183 | $66.61 | $744,900 | 2024-02-05 |
| Hineline Lawrence J. | Grant, award...etc | 11,183 | 2024-02-05 | ||
| Durgam Suresh K. | Sale | -6,167 | $66.69 | $411,277 | 2024-02-05 |
| Durgam Suresh K. | Grant, award...etc | 11,860 | 2024-02-05 | ||
| Mates Sharon | Sale | -191,362 | $66.38 | $12,702,610 | 2024-01-18 |
| Mates Sharon | Derivatives Exercise | 191,362 | 2024-01-18 | ||
| Halstead Michael | Sale | -50,000 | $66.31 | $3,315,500 | 2024-01-12 |
| Halstead Michael | Derivatives Exercise | 50,000 | 2024-01-12 | ||
| Durgam Suresh K. | Sale | -62,282 | $70.41 | $4,385,276 | 2024-01-04 |
| Durgam Suresh K. | Derivatives Exercise | 62,282 | 2024-01-04 | ||
| RIGGS RORY B | Grant, award...etc | 251 | $71.62 | 2024-01-03 | |
| VAN NOSTRAND ROBERT L | Grant, award...etc | 76 | $71.62 | 2024-01-03 | |
| Durgam Suresh K. | Sale | -21,262 | $65 | $1,382,030 | 2023-12-15 |
| Halstead Michael | Sale | -50,000 | $53.37 | $2,668,500 | 2023-11-14 |
| Halstead Michael | Derivatives Exercise | 50,000 | 2023-11-14 | ||
| Neumann Mark | Sale | -42,393 | $55.98 | $2,373,232 | 2023-11-08 |
| Neumann Mark | Derivatives Exercise | 26,754 | 2023-11-08 |
The information provided in this report about ITCI stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Intra-Cellular Therapies, Inc(NASDAQ:ITCI) 
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases, and other disorders of the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It i...
Founded: 2002
Full Time Employees: 330
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends